Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SynthRx Inc.

Division of Mast Therapeutics Inc./SynthRx Inc.

Latest From SynthRx Inc.

Mast Therapeutics Changes Its Name In Hopes Of A Fresh Start

Formerly called Adventrx, the company says the name Mast better reflects its current strategy, which includes a focus on a Phase III asset for sickle cell disease. With a new name and a late-stage trial underway, management is hoping to persuade skeptical investors to take a second look.

BioPharmaceutical Clinical Trials

Deals Shaping the Medical Industry (03/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Mast Therapeutics Inc.
  • Savara Inc.
  • Senior Management
  • Contact Info
  • SynthRx Inc.
    Phone: (713) 500-5301
    4606 Willow St.
    Bellaire , TX 77401